Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Hypersensitivity Pneumonitis | Research

Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retrospective cohort study

Authors: Małgorzata Sobiecka, Monika Szturmowicz, Katarzyna Lewandowska, Agata Kowalik, Ewa Łyżwa, Katarzyna Zimna, Inga Barańska, Lilia Jakubowska, Jan Kuś, Renata Langfort, Witold Tomkowski

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis share commonalities in pathogenesis shifting haemostasis balance towards the procoagulant and antifibrinolytic activity. Several studies have suggested an increased risk of venous thromboembolism in IPF. The association between venous thromboembolism and chronic hypersensitivity pneumonitis has not been studied yet.

Methods

A retrospective cohort study of IPF and chronic hypersensitivity pneumonitis patients diagnosed in single tertiary referral center between 2005 and 2018 was conducted. The incidence of symptomatic venous thromboembolism was evaluated. Risk factors for venous thromboembolism and survival among those with and without venous thromboembolism were assessed.

Results

A total of 411 (259 IPF and 152 chronic hypersensitivity) patients were included (mean age 66.7 ± 8.4 vs 51.0 ± 13.3 years, respectively). There were 12 (4.6%) incident cases of venous thromboembolism in IPF and 5 (3.3%) in chronic hypersensitivity pneumonitis cohort. The relative risk (RR) of venous thromboembolism in chronic hypersensitivity pneumonitis was not significantly different to that found in patients with IPF (7.1 vs 11.8/1000 person-years, RR 1.661 95% CI 0.545–6.019, respectively).
The treatment with systemic steroids (OR 5.38; 95% CI 1.65–18.8, p = 0.006) and GAP stage 3 (OR 7.85; 95% CI 1.49–34.9; p = 0.037) were significant risk factors for venous thromboembolism in IPF. Arterial hypertension and pulmonary hypertension significantly increased risk of venous thromboembolism in chronic hypersensitivity pneumonitis. There were no significant differences in survival between patients with and without venous thromboembolism.

Conclusions

The patients with chronic hypersensitivity pneumonitis have a marked increase in the risk of venous thromboembolism, similar to the patients with IPF. Venous thromboembolism does not affect the survival of patients with IPF and chronic hypersensitivity pneumonitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202:e36–69.CrossRef Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202:e36–69.CrossRef
2.
go back to reference Günther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000;83:853–60.CrossRef Günther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000;83:853–60.CrossRef
3.
go back to reference Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.CrossRef Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.CrossRef
4.
go back to reference Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.CrossRef Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.CrossRef
5.
go back to reference Chambers RC. Procoagulant signaling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153:S367–78.CrossRef Chambers RC. Procoagulant signaling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153:S367–78.CrossRef
7.
go back to reference Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res. 2000;99:111–7.CrossRef Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res. 2000;99:111–7.CrossRef
8.
go back to reference Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res. 1995;77:493–504.CrossRef Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res. 1995;77:493–504.CrossRef
9.
go back to reference Hubbard RB, Smith Ch, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178:1257–61.CrossRef Hubbard RB, Smith Ch, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178:1257–61.CrossRef
10.
go back to reference Sode BF, Dahk M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med. 2010;181:1085–92.CrossRef Sode BF, Dahk M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med. 2010;181:1085–92.CrossRef
11.
go back to reference Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–32.CrossRef Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–32.CrossRef
12.
go back to reference Navaratnam V, Fogarty AW, McKeever T, Thompson N, Jenkins G, Johnson SR, et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax. 2014;69:207–15.CrossRef Navaratnam V, Fogarty AW, McKeever T, Thompson N, Jenkins G, Johnson SR, et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax. 2014;69:207–15.CrossRef
13.
go back to reference Dalleywater W, Powell HA, Fogarty AW, Hubbard RB, Navaratnam V. Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study. Eur Respir J. 2014;44:1714–5.CrossRef Dalleywater W, Powell HA, Fogarty AW, Hubbard RB, Navaratnam V. Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study. Eur Respir J. 2014;44:1714–5.CrossRef
15.
go back to reference Szturmowicz M, Garczewska B, Jędrych ME, Bartoszuk I, Sobiecka M, Tomkowski W, et al. The value of serum precipitins against specific antigens in patients diagnosed with hypersensitivity pneumonitis – retrospective study. Centr Eur J Immunol. 2019;44:390–4.CrossRef Szturmowicz M, Garczewska B, Jędrych ME, Bartoszuk I, Sobiecka M, Tomkowski W, et al. The value of serum precipitins against specific antigens in patients diagnosed with hypersensitivity pneumonitis – retrospective study. Centr Eur J Immunol. 2019;44:390–4.CrossRef
16.
go back to reference Selman M, Buendia-Roldan I. Immunopathology, diagnosis, and management of hypersensitivity pneumonitis. Semin Respir Crit Care Med. 2012;33(5):543–54.CrossRef Selman M, Buendia-Roldan I. Immunopathology, diagnosis, and management of hypersensitivity pneumonitis. Semin Respir Crit Care Med. 2012;33(5):543–54.CrossRef
17.
go back to reference Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680–9.CrossRef Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680–9.CrossRef
18.
go back to reference Szturmowicz M, Barańska I, Jędrych ME, Bartoszuk I, Radwan Roehrenschef P, Roży A, et al. Hypersensitivity pneumonitis recognised in a single pulmonary unit, between 2005 and 2015—comparision with recently proposed diagnostic criteria. Adv Respir Med. 2019;87(2):83–9.CrossRef Szturmowicz M, Barańska I, Jędrych ME, Bartoszuk I, Radwan Roehrenschef P, Roży A, et al. Hypersensitivity pneumonitis recognised in a single pulmonary unit, between 2005 and 2015—comparision with recently proposed diagnostic criteria. Adv Respir Med. 2019;87(2):83–9.CrossRef
20.
go back to reference Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res. 2016;145:27–33.CrossRef Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res. 2016;145:27–33.CrossRef
21.
go back to reference Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–64.CrossRef Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–64.CrossRef
22.
go back to reference Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–93.CrossRef Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–93.CrossRef
23.
go back to reference Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2009;21:722–7.CrossRef Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2009;21:722–7.CrossRef
24.
go back to reference Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611–7.CrossRef Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611–7.CrossRef
25.
go back to reference Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;26:e813–21. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;26:e813–21.
26.
go back to reference Vasakowa M, Selman M, Morell F, Streclova M, Molina-Molina M, Raghu G. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med. 2019;200:301–8.CrossRef Vasakowa M, Selman M, Morell F, Streclova M, Molina-Molina M, Raghu G. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med. 2019;200:301–8.CrossRef
27.
go back to reference Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639–47.CrossRef Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639–47.CrossRef
28.
go back to reference Khan F, Tritschel T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398:64–77.CrossRef Khan F, Tritschel T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398:64–77.CrossRef
29.
go back to reference Boonpheng B, Ungprasert P. Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systemic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35:109–14.PubMedPubMedCentral Boonpheng B, Ungprasert P. Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systemic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35:109–14.PubMedPubMedCentral
30.
go back to reference Lal A, Akhtar J, Pinto S, Grewal H, Martin K. Recurrent pulmonary embolism and hypersensitivity pneumonitis secondary to Aspergillus, in a compost plant worker: case report and review of literature. Lung. 2018;196:553–60.CrossRef Lal A, Akhtar J, Pinto S, Grewal H, Martin K. Recurrent pulmonary embolism and hypersensitivity pneumonitis secondary to Aspergillus, in a compost plant worker: case report and review of literature. Lung. 2018;196:553–60.CrossRef
31.
go back to reference Wälscher J, Gross B, Morisset J, Johannson KA, Vasakova M, Bruhwyler J, et al. Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respir Res. 2020;21:12.CrossRef Wälscher J, Gross B, Morisset J, Johannson KA, Vasakova M, Bruhwyler J, et al. Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respir Res. 2020;21:12.CrossRef
32.
go back to reference Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic pulmonary fibrosis clinical research network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.CrossRef Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic pulmonary fibrosis clinical research network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.CrossRef
33.
go back to reference Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism. A nationwide population-based case-control study. JAMA Intern Med. 2013;173:743–52.CrossRef Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism. A nationwide population-based case-control study. JAMA Intern Med. 2013;173:743–52.CrossRef
34.
go back to reference Johnson SR, Hakami N, Ahmad Z, Wijeysundera DN. Venous thromboembolism in systemic sclerosis: prevalence, risk factors, and effect on survival. J Rheumatol. 2018;45:6.CrossRef Johnson SR, Hakami N, Ahmad Z, Wijeysundera DN. Venous thromboembolism in systemic sclerosis: prevalence, risk factors, and effect on survival. J Rheumatol. 2018;45:6.CrossRef
Metadata
Title
Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retrospective cohort study
Authors
Małgorzata Sobiecka
Monika Szturmowicz
Katarzyna Lewandowska
Agata Kowalik
Ewa Łyżwa
Katarzyna Zimna
Inga Barańska
Lilia Jakubowska
Jan Kuś
Renata Langfort
Witold Tomkowski
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01794-y

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.